Auxilium Pharmaceuticals has no intention of accepting a multibillion-dollar bid from Endo, the company said, preferring to stay the course and pull off an en-vogue tax inversion as it looks to cut costs.
Speculation has been brewing all year about the prospect of Germany's Merck KGaA turning to M&A to bolster its unproductive drug pipeline, and today the company confirmed it has struck a deal, agreeing to buy Sigma-Aldrich for $17 billion.
Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion.
PCI, a contract pharma packaging company, has snapped up clinical trial supply operation Biotec, expanding its footprint across all phases of drug development.
Now that Bayer has announced a planned spinoff of its plastics business, all eyes are on what it may do with the proceeds. And the way some analysts see it, that money could go toward a pickup of animal health company Zoetis.
Who's afraid of a tax-inversion crackdown? Not Illinois-based Horizon Pharma, which plans to move its corporate address to Ireland today.
Endo's got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it's swallowed a poison pill to make sure it gets just that.
In its latest product acquisition, Integra LifeSciences is buying instrumentation lines from Medtronic for $60 million in cash. These include about 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments. The surgical products company will also gain a manufacturing facility in St. Aubin le Monial, France.
Just a few days after Auxilium Pharmaceuticals put out the word that pressure on the sales side was forcing a restructuring and the elimination of about 200 jobs, Endo has come along with a proposal to buy out the company for about $2.2 billion worth of cash and stock.
After months of battling between Allergan and its pursuers, Valeant and Pershing Square Capital Management, the two sides have reached a truce--at least when it comes to an upcoming shareholder meeting.